NCT07082868View on ClinicalTrials.gov

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Primary Central Nervous System Lymphoma (PCNSL)Primary Central Nervous System LymphomaRelapsed Primary Central Nervous System LymphomaRefractory Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma (SCNSL)
Interventions
DRUG

ibrutinib

Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day

DRUG

Epcoritamab

Epcoritamab will be administered at the study site clinic, as a SC injection

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

84112

NOT_YET_RECRUITING

University of Utah, Salt Lake City

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER